These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
802 related articles for article (PubMed ID: 24743607)
21. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands. Vugts G; Maaskant-Braat AJ; de Roos WK; Voogd AC; Nieuwenhuijzen GA Eur J Surg Oncol; 2016 Jul; 42(7):956-64. PubMed ID: 27107791 [TBL] [Abstract][Full Text] [Related]
22. Diagnostic accuracy of de-escalated surgical procedure in axilla for node-positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta-analysis. Song YX; Xu Z; Liang MX; Liu Z; Hou JC; Chen X; Xu D; Fei YJ; Tang JH Cancer Med; 2022 Nov; 11(22):4085-4103. PubMed ID: 35502768 [TBL] [Abstract][Full Text] [Related]
23. [The feasibility and the role of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer]. Péley G; Török K; Farkas E; Mátrai Z; Horváth Z; Sinkovics I; Hitre E; Rényi-Vámos F; Orosz Z; Köves I Magy Onkol; 2006; 50(1):19-23. PubMed ID: 16617379 [TBL] [Abstract][Full Text] [Related]
24. Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancer. Simons JM; van Pelt MLMA; Marinelli AWKS; Straver ME; Zeillemaker AM; Pereira Arias-Bouda LM; van Nijnatten TJA; Koppert LB; Hunt KK; Smidt ML; Luiten EJT; van der Pol CC Br J Surg; 2019 Nov; 106(12):1632-1639. PubMed ID: 31593294 [TBL] [Abstract][Full Text] [Related]
25. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Veronesi U; Paganelli G; Galimberti V; Viale G; Zurrida S; Bedoni M; Costa A; de Cicco C; Geraghty JG; Luini A; Sacchini V; Veronesi P Lancet; 1997 Jun; 349(9069):1864-7. PubMed ID: 9217757 [TBL] [Abstract][Full Text] [Related]
26. Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy. Pecha V; Kolarik D; Kozevnikova R; Hovorkova K; Hrabetova P; Halaska M; Sottner O; Trnkova M; Petruzelka L; Kolarova H Cancer; 2011 Oct; 117(20):4606-16. PubMed ID: 21437896 [TBL] [Abstract][Full Text] [Related]
27. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. Brady EW Breast J; 2002; 8(2):97-100. PubMed ID: 11896755 [TBL] [Abstract][Full Text] [Related]
28. Sentinel node biopsy before neoadjuvant chemotherapy spares breast cancer patients axillary lymph node dissection. van Rijk MC; Nieweg OE; Rutgers EJ; Oldenburg HS; Olmos RV; Hoefnagel CA; Kroon BB Ann Surg Oncol; 2006 Apr; 13(4):475-9. PubMed ID: 16485148 [TBL] [Abstract][Full Text] [Related]
29. Targeted axillary dissection with preoperative tattooing of biopsied positive axillary lymph nodes in breast cancer. Gatek J; Petru V; Kosac P; Ratajsky M; Duben J; Dudesek B; Jancik P; Zabojnikova M; Katrusak J; Opelova P; Podrazska L; Vazan P; Kudlova P; Holik P; Melichar B; Vrana D Neoplasma; 2020 Nov; 67(6):1329-1334. PubMed ID: 32749847 [TBL] [Abstract][Full Text] [Related]
30. Gamma-probe-guided resection of the sentinel lymph node in breast cancer. Crossin JA; Johnson AC; Stewart PB; Turner WW Am Surg; 1998 Jul; 64(7):666-8; discussion 669. PubMed ID: 9655279 [TBL] [Abstract][Full Text] [Related]
31. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients. Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881 [TBL] [Abstract][Full Text] [Related]
32. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients. Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417 [TBL] [Abstract][Full Text] [Related]
33. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy. Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734 [TBL] [Abstract][Full Text] [Related]
34. Sentinel lymph node biopsy after neoadjuvant systemic chemotherapy in patients with breast cancer: a prospective pilot trial. Medina-Franco H; Salgado-Nesme N; Zerón-Medina-Cuairán J Rev Invest Clin; 2008; 60(5):390-4. PubMed ID: 19227436 [TBL] [Abstract][Full Text] [Related]
35. Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment. Siso C; Esgueva A; Rivero J; Morales C; Miranda I; Peg V; Gil-Moreno A; Espinosa-Bravo M; Rubio IT Eur J Surg Oncol; 2023 Oct; 49(10):106938. PubMed ID: 37244843 [TBL] [Abstract][Full Text] [Related]
36. Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review. Schipper RJ; Moossdorff M; Beets-Tan RGH; Smidt ML; Lobbes MBI Eur J Radiol; 2015 Jan; 84(1):41-47. PubMed ID: 25458227 [TBL] [Abstract][Full Text] [Related]
37. Combined procedure of marking axillary positive node with iodine-125 seed and sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy. Custodio Rebollo Aguirre A; Sánchez Sánchez R; González Jiménez AD; Culiañez Casas M; Mendoza Arnau I; Rashki M; Rudolphi Solero T; Martínez Meca S Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(2):75-83. PubMed ID: 31759957 [TBL] [Abstract][Full Text] [Related]
38. Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial. Schwentner L; Helms G; Nekljudova V; Ataseven B; Bauerfeind I; Ditsch N; Fehm T; Fleige B; Hauschild M; Heil J; Kümmel S; Lebeau A; Schmatloch S; Schrenk P; Staebler A; Loibl S; Untch M; Von Minckwitz G; Liedtke C; Kühn T Breast; 2017 Feb; 31():202-207. PubMed ID: 27889596 [TBL] [Abstract][Full Text] [Related]
39. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784 [TBL] [Abstract][Full Text] [Related]
40. Axillary ultrasound for prediction of response to neoadjuvant therapy in the context of surgical strategies to axillary dissection in primary breast cancer: a systematic review of the current literature. Banys-Paluchowski M; Gruber IV; Hartkopf A; Paluchowski P; Krawczyk N; Marx M; Brucker S; Hahn M Arch Gynecol Obstet; 2020 Feb; 301(2):341-353. PubMed ID: 31897672 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]